FDA Expands Dolutegravir Approval to Infants With HIV-1 Weighing at Least 2 kg

Reports

4

Domains carrying it

4

First reported

26 August 2026

Latest report

3 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 26 August 2026FDA greenlights ViiV's Tivicay PD for HIV-positive newborns in first month of lifedrugdiscoverytrends.com
2. 28 August 2026Dolutegravir Antiretroviral Receives FDA Approval for Newborns With HIVmedscape.com
3. 3 September 2026FDA approves Tivicay pd for youngest HIV patientspharmatimes.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• FDA Approves Bixlenvo, a Single Tablet Option for Adults With HIV4 reports · 4 domains · 31 August 2026
• FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune ...11 reports · 11 domains · 1 September 2026
• FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia11 reports · 10 domains · 2 September 2026
• FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease2 reports · 2 domains · 4 September 2026
• FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a6 reports · 6 domains · 22 August 2026
• US FDA approves Replimune's skin cancer drug15 reports · 14 domains · 10 August 2026

◆ Share

◆ Evidence

4 reports · 4 domains

• FDA approves Tivicay pd for youngest HIV patientspharmatimes.com · 3 September 2026
• Dolutegravir Antiretroviral Receives FDA Approval for Newborns With HIVmedscape.com · 28 August 2026
• FDA Expands Dolutegravir Approval to Infants With HIV-1 Weighing at Least 2 kgpatientcareonline.com · 26 August 2026
• FDA greenlights ViiV's Tivicay PD for HIV-positive newborns in first month of lifedrugdiscoverytrends.com · 26 August 2026